BioNTech (NASDAQ:BNTX) Rating Increased to Hold at Wall Street Zen

BioNTech (NASDAQ:BNTX) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

BNTX has been the topic of several other reports. Morgan Stanley lowered their price objective on shares of BioNTech from $140.00 to $132.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 6th. The Goldman Sachs Group assumed coverage on BioNTech in a research report on Thursday, May 29th. They issued a “neutral” rating and a $110.00 target price for the company. BMO Capital Markets upped their price target on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research report on Tuesday, March 11th. Citigroup reissued a “buy” rating and issued a $140.00 price objective (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th. Finally, JPMorgan Chase & Co. lowered their target price on BioNTech from $120.00 to $116.00 and set a “neutral” rating on the stock in a research note on Thursday, May 22nd. Five equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $138.25.

BioNTech Price Performance

NASDAQ BNTX opened at $108.49 on Friday. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a market cap of $26.08 billion, a PE ratio of -51.66 and a beta of 1.29. The stock’s 50-day moving average price is $99.26 and its two-hundred day moving average price is $108.40.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same period last year, the firm posted $1.90 earnings per share. On average, analysts predict that BioNTech will post -3.88 EPS for the current year.

Institutional Trading of BioNTech

A number of institutional investors have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise acquired a new position in shares of BioNTech during the 1st quarter worth $36,000. Jones Financial Companies Lllp boosted its holdings in BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after purchasing an additional 246 shares in the last quarter. Banque Transatlantique SA bought a new stake in BioNTech in the first quarter worth $80,000. Quintet Private Bank Europe S.A. increased its position in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after buying an additional 700 shares during the last quarter. Finally, Allianz SE acquired a new position in BioNTech during the fourth quarter worth $90,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.